Alpha Crest Capital Management LLC Nektar Therapeutics Transaction History

Alpha Crest Capital Management LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$3.17 - $6.17 $49,439 - $96,227	-15,596 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$4.16 - $13.72 $268,340 - $885,008	-64,505 Reduced 80.53%	15,596 $84,000
Q4 2021 Feb 09, 2022	BUY	$10.83 - $18.41 $632,526 - $1.08 Million	58,405 Added 269.2%	80,101 $1.08 Million
Q3 2021 Nov 10, 2021	SELL	$13.07 - $18.84 $1.31 Million - $1.89 Million	-100,415 Reduced 82.23%	21,696 $390,000
Q2 2021 Aug 12, 2021	BUY	$16.52 - $20.4 $1.83 Million - $2.26 Million	110,598 Added 960.64%	122,111 $2.1 Million
Q1 2021 May 13, 2021	SELL	$16.56 - $25.46 $12,403 - $19,069	-749 Reduced 6.11%	11,513 $230,000
Q4 2020 Feb 12, 2021	SELL	$15.77 - $19.03 $106,573 - $128,604	-6,758 Reduced 35.53%	12,262 $208,000
Q3 2020 Nov 12, 2020	BUY	$16.59 - $24.79 $315,541 - $471,505	19,020 New	19,020 $316,000
Q4 2019 Feb 12, 2020	SELL	$15.87 - $23.12 $233,225 - $339,771	-14,696 Closed	0 $0
Q3 2019 Nov 12, 2019	BUY	$16.91 - $36.27 $248,509 - $533,023	14,696 New	14,696 $268,000

145

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $171M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Alpha Crest Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Crest Capital Management LLC with notifications on news.